-=Intrexon (XON) reported earnings on Thur 28 Feb 19 (a/h)

Intrexon misses by $2.46, beats on revs

• Reports Q4 (Dec) loss of $2.59 per share, $2.46 worse than the single analyst estimate of ($0.13); revenues fell 43.9% year/year to $43.19 mln vs the $42.61 mln S&P Capital IQ Consensus.
• Collaboration and licensing revenues decreased $68.7 million from the year ended December 31, 2017 primarily due to (i) the mutual termination in 2017 of the Company's second ECC with Ziopharm for the treatment of graft-versus-host disease
• Based on Intrexon's financial position, including its cash, cash equivalents and short-term investments of $224 million at December 31, 2018, in connection with issuing its financial statements Intrexon expects to include a conclusion in its Form 10-K that there is substantial doubt about its ability to continue as a going concern.

-=Intrexon (XON) : advances in production of medical cannabis

Intrexon announces advances in the development of its microbial platform to produce cannabinoids for medical uses

Through Intrexon's proprietary technologies, the Company has engineered a yeast strain to produce low-cost, robust and consistent cannabinoid outputs via fermentation. This process utilizing microbes has potential to provide greater supply-chain security, and avoids the resource-intensive isolation that often leads to quality and quantity variability in end products.

• Further, this versatile strain was designed to enable the production of cannabinoids that only are produced today in miniscule amounts in cannabis plants as well as novel cannabinoids. The Company has scaled the process and achieved titers approaching commercially relevant targets with anticipated production of pure cannabinoids at COGS less than $1,000/kg.